How to Get GLP-1 Coverage on Medicare in 2026: A Provider's Guide to the New Bridge Program

Headlines this month have been celebrating a milestone: starting July 1, 2026, eligible Medicare beneficiaries will be able to access certain GLP-1 medications for $50 per month. For a population that has watched these drugs reshape obesity care from the outside, this feels overdue. It is also more complicated than the headlines suggest.

If you are a provider, a pharmacy, a digital health platform, an MSO, or a benefits team, the operational details of the new Medicare GLP-1 Bridge are going to matter a great deal. This is not a normal Part D coverage expansion. It is a short-term demonstration program with a separate payment rail, narrow drug eligibility, specific clinical criteria, and several wrinkles that will catch unprepared organizations off guard.

Here is what is actually happening, what it means, and what to do about it.

What the Bridge Actually is

The Medicare GLP-1 Bridge is a short-term demonstration that runs from July 1, 2026 through December 31, 2027. It was originally designed as a six-month bridge to a longer-term program called the BALANCE Model, which was supposed to launch in Part D in 2027. When not enough Part D plans signed on to BALANCE by the April 2026 deadline, CMS extended the Bridge to 18 months instead. So what we have now is an 18-month demonstration with no clearly defined permanent successor.

Beneficiaries who qualify pay a flat $50 copay per month, regardless of dosage and regardless of which phase of the Part D benefit they are otherwise in. Manufacturers have agreed to a net price of $245 per month. The program operates outside the standard Part D claims pipeline. CMS is using a single central processor, Humana, which already runs the Limited Income Newly Eligible Transition program, to handle prior authorization, claims adjudication, and pharmacy reimbursement. Part D plans do not opt in, do not bear financial risk, and are not involved in the operational flow.

Which Drugs are Covered, and which are not

As of CMS's most recent guidance, the Bridge covers all formulations of Foundayo, all formulations of Wegovy including the tablet, and the KwikPen formulation of Zepbound. The single-dose vial and single-dose pen formulations of Zepbound are not included.

The Bridge covers these drugs only when prescribed for weight reduction or weight maintenance. If a beneficiary has a Medicare-coverable use for the same drug under standard Part D rules, such as Wegovy for cardiovascular risk reduction in patients with established cardiovascular disease, or Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, that prescription does not flow through the Bridge. It runs through the patient's regular Part D plan and follows normal formulary and cost-sharing rules. Same drug, different lane, depending on indication.

Mounjaro and Ozempic are not covered under the Bridge for weight loss. If a patient is taking Ozempic or Mounjaro for type 2 diabetes, that continues to flow through standard Part D coverage.

Who Qualifies

To use the Bridge, a beneficiary must be enrolled in a standalone Part D prescription drug plan or a Medicare Advantage plan with prescription drug coverage. A medical provider must submit a prior authorization request to the central processor. The PA must attest that the drug is being prescribed to reduce excess body weight and maintain weight reduction in combination with ongoing lifestyle modification, including structured nutrition and physical activity consistent with FDA labeling.

The clinical criteria fall into three buckets. A beneficiary qualifies if they are 18 or older and meet one of the following at the time GLP-1 therapy was initiated: a BMI greater than or equal to 35, a BMI greater than or equal to 30 with a diagnosis of heart failure with preserved ejection fraction or uncontrolled hypertension or chronic kidney disease stage 3a or higher, or a BMI greater than or equal to 27 with a diagnosis of prediabetes, prior myocardial infarction, prior stroke, or symptomatic peripheral artery disease.

There is a meaningful nuance in how BMI is evaluated. The criteria apply at the time of GLP-1 therapy initiation, not at the time of the prior authorization. CMS has explicitly said that a patient who started GLP-1 therapy in 2024 with a BMI of 37 and now has a BMI of 34 because the drug is working would still qualify, because they met the BMI threshold when therapy began. The provider attests to the historical BMI in the PA. This is going to be a significant operational and documentation issue. Providers do not need to be enrolled as Medicare providers to write a prescription or submit a PA under this program. That is a deliberate access decision.

The Wrinkles That are Going to Catch People

The $50 copay does not count toward the Part D deductible. It also does not count toward the $2,100 annual out-of-pocket cap for Part D drugs. Low-income cost-sharing subsidies do not apply. For a beneficiary on multiple expensive medications, this means GLP-1 spending under the Bridge sits entirely outside the financial protections of Part D.

The Bridge ends December 31, 2027. There is currently no defined permanent program to succeed it. CMS has signaled that beneficiaries who participate in the Bridge will need to enroll in a 2027 Part D plan that has opted into BALANCE in order to maintain access, but BALANCE is not actually launching in Part D in 2027 as originally planned. This means tens of thousands or potentially millions of beneficiaries could face a coverage cliff at the end of 2027 with no clear off-ramp. Expect significant patient education and political pressure between now and then.

KFF and others have noted that since the Bridge sits outside Part D, manufacturers are not subject to the standard Part D price discount obligations on these drugs. The federal government bears most of the cost. Estimates from independent analysts suggest the Bridge will cost Medicare in the range of billions of dollars per year, depending on uptake. CMS has not published its own cost projections.

What providers, pharmacies, and platforms need to do before July 1

For prescribing providers

Build a workflow for documenting BMI at the time of GLP-1 initiation, especially for patients who started therapy years ago. The PA attestation requires the historical value. If your charting does not surface that cleanly, you will be doing chart dives in real time. Update your patient intake and refill workflows now.

Make sure your team can distinguish between the Bridge pathway and standard Part D coverage for the same drug. Wegovy for weight loss is the Bridge. Wegovy for cardiovascular risk reduction in eligible patients is standard Part D. Zepbound for weight loss with KwikPen formulation is the Bridge. Zepbound for sleep apnea is standard Part D. Same medication, different rules, different cost to patient, different prior authorization process. Train your staff.

For pharmacies

CMS has indicated that pharmacies will use specific BIN and PCN values to route Bridge claims to the central processor. Pharmacies will collect the $50 copay at the counter and be reimbursed at no less than wholesale acquisition cost, minus the copay, plus a dispensing fee. Pharmacies do not need to opt in. But they do need their systems configured to recognize and route Bridge claims correctly. Do not assume your PBM will handle it silently.

For digital health platforms and weight management programs

If you are operating in the obesity, metabolic, or cardiometabolic space, the Bridge changes the unit economics for a meaningful slice of your patient base. Older patients who were previously cash-pay or excluded from Medicare coverage now have a path. Patients who were on commercial coverage before aging into Medicare have a way to continue therapy. Build the patient education materials, the eligibility screener, and the PA support workflow now, not in June.

Be careful with marketing claims. The CMS guidance includes a lifestyle modification attestation. If your business model is medication-only with no behavioral or nutritional support, you may run into PA scrutiny. The Bridge expects, on paper, that GLP-1 therapy is paired with structured nutrition and physical activity.

For MSOs and benefit consultants

Help your physician clients think through whether they want to operate in the Bridge pathway, the standard Part D pathway, or both. The Bridge has lower clinical documentation burden in some respects, since the PA is attestation-based, but it sits outside Part D's appeal infrastructure for the most part. Standard Part D has more procedural protections but more formulary friction. Different pathways serve different patients.

The bigger picture

This is not a clean story of Medicare expanding coverage for obesity. It is a temporary, narrowly defined demonstration that creates a parallel claims rail outside the normal Part D benefit, with attractive patient economics and significant unanswered questions about what happens at the end of 2027. It will substantially expand access to GLP-1s for older Americans who could not afford them. It will also create operational complexity, documentation burden, and a coverage cliff that is currently scheduled to land right after a presidential election.

If you are a provider or operator in this space, I would not wait until June to figure out the workflow. The patients are going to ask. The answer is more nuanced than the headline.

Build the workflow. Document the BMI history. Train the team. Watch what happens with BALANCE.

And keep an eye on December 2027. That is the date that matters.